# Research Report: Adalimumab

**Generated:** 2025-12-25 15:24:44
**Report ID:** 7473b662-afe5-43c6-a99d-f72e7d0bb804

---

## Table of Contents

1. iqvia_insights
2. clinical_trials
3. patent_landscape

---

## iqvia_insights

**Market Analysis for Adalimumab**

ğŸ“Š **Current Market Size:** $2,852.96M
ğŸ“ˆ **5-Year CAGR:** 9.39%
ğŸ¯ **2028 Forecast:** $4,085.76M

**Top Markets:** China, Germany, USA
**Market Leader:** Novartis

The neurology segment shows strong growth trajectory.

---

## clinical_trials

**Clinical Trials Analysis: Adalimumab**

ğŸ“Š **Total Trials:** 13
âœ… **Active Trials:** 6
ğŸ‘¥ **Total Enrollment:** 14,631 patients
ğŸ¯ **Indication:** neurology

**Phase Distribution:**
â€¢ Phase 1: 2 trials
â€¢ Phase 1/2: 2 trials
â€¢ Phase 2: 4 trials
â€¢ Phase 2/3: 1 trials
â€¢ Phase 3: 1 trials
â€¢ Phase 4: 3 trials

**Top Sponsors:**
â€¢ AstraZeneca
â€¢ Gilead Sciences
â€¢ Novartis

**Development Status:**
â€¢ Early development stage
â€¢ Multiple sponsors active

---

## patent_landscape

**Patent Landscape Analysis: Adalimumab**

ğŸ“‹ **Total Patents:** 5
âœ… **Active Patents:** 3
ğŸ“… **Earliest Expiry:** 2031-10-23
âš–ï¸ **FTO Status:** Potential Issues ğŸŸ¡ Potential Issues
ğŸ”„ **Litigation History:** Yes

**Key Patent Holders:**
â€¢ Bristol-Myers Squibb
â€¢ Johnson & Johnson
â€¢ AbbVie

**Strategic Implications:**
â€¢ Strong IP protection continues
â€¢ Consider licensing discussions

---

## Data Tables

### Market Size Analysis - Adalimumab

| Year | Market Size (USD M) | Growth Rate (%) |
| --- | --- | --- |
| 2019 | 1821.06 | 12.8 |
| 2020 | 2031.15 | 11.5 |
| 2021 | 2310.56 | 13.8 |
| 2022 | 2574.46 | 11.4 |
| 2023 | 2704.46 | 5.0 |
| 2024 | 2852.96 | 5.5 |

### Clinical Trials - Adalimumab

| NCT ID | Phase | Status | Sponsor | Enrollment | Start Date |
| --- | --- | --- | --- | --- | --- |
| NCT69883005 | Phase 3 | Completed | Novartis | 1147 | 2025-01-18 |
| NCT51268661 | Phase 4 | Enrolling by invitation | Bayer | 1970 | 2021-03-11 |
| NCT18671375 | Phase 4 | Active, not recruiting | Eli Lilly | 1435 | 2022-07-20 |
| NCT11471412 | Phase 2 | Active, not recruiting | Novo Nordisk | 1054 | 2022-07-03 |
| NCT19491344 | Phase 2 | Not yet recruiting | AstraZeneca | 842 | 2024-03-23 |
| NCT76428179 | Phase 1 | Not yet recruiting | Gilead Sciences | 857 | 2025-01-27 |
| NCT14102291 | Phase 1/2 | Enrolling by invitation | Novo Nordisk | 1779 | 2025-04-22 |
| NCT15793004 | Phase 1 | Recruiting | Eli Lilly | 676 | 2025-03-29 |
| NCT91812258 | Phase 2 | Active, not recruiting | Novo Nordisk | 1747 | 2024-06-17 |
| NCT28055718 | Phase 4 | Active, not recruiting | Novartis | 249 | 2023-10-19 |

### Patent Portfolio - Adalimumab

| Patent Number | Type | Assignee | Filing Date | Expiry Date | Status |
| --- | --- | --- | --- | --- | --- |
| US8941146 | Formulation | Bayer | 2022-10-25 | 2042-10-20 | Active |
| US8749827 | Compound | Bristol-Myers Squibb | 2006-12-19 | 2026-12-14 | Expired |
| US9534629 | Compound | Johnson & Johnson | 2011-10-28 | 2031-10-23 | Active |
| US10760385 | Process | AbbVie | 2007-12-02 | 2027-11-27 | Expired |
| US8345243 | Use | Roche | 2014-09-02 | 2034-08-28 | Active |

## References

- EU Clinical Trials Register
- WIPO
- IQVIA MIDAS Database
- USPTO Patent Database
- European Patent Office
- ClinicalTrials.gov
- IQVIA National Sales Perspectives
- WHO ICTRP
